{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-18T15:18:17.704Z","profile":{"slug":"teriparatide","name":"Teriparatide","aliases":[],"category":"Recombinant human parathyroid hormone fragment (PTH 1-34)"},"synthesis":{"mechanism":"Teriparatide is the recombinant 1–34 amino-acid fragment of human parathyroid hormone and retains the receptor-active N-terminal region of PTH. Intermittent subcutaneous exposure activates PTH1 receptors in bone and kidney; in bone it increases osteoblast activity and remodeling, producing an anabolic treatment effect when used according to an approved regimen. Its effects depend on exposure pattern: intermittent therapeutic administration is not equivalent to sustained endogenous parathyroid-hormone excess. Evidence and authorization are formulation-, indication-, population-, duration-, and sequence-specific.","evidence":"The governed 25-source corpus includes pivotal and comparative randomized trials, long-term follow-up, systematic reviews and network meta-analyses, pharmacologic and biosimilarity studies, real-world safety surveillance, sequential-treatment studies, and research in postmenopausal, glucocorticoid-induced, and other high-fracture-risk osteoporosis contexts. The archive separately labels fracture endpoints, bone-mineral-density and turnover surrogates, treatment sequencing, fracture-healing hypotheses, special populations, and safety. PubMed identities, titles, authorship, publication metadata, DOI/PMID, teriparatide relevance, source status, and duplication were verified. Study-design grades remain provisional pending accountable claim-level review.","safety":"Important risks and limitations include hypercalcemia, orthostatic symptoms, nausea, leg cramps, urolithiasis considerations, and population-specific restrictions and warnings in current labeling. Use in patients with increased baseline risk of osteosarcoma or certain metabolic bone conditions requires careful application of current contraindications and warnings. Animal toxicology findings must not be translated directly into a human risk estimate. Apparent benefits in fracture healing, spinal fusion, osteonecrosis of the jaw, or populations outside labeled indications remain context-dependent and should not be presented as established routine uses.","observationalBoundary":"Teriparatide has a large human evidence base supporting an anabolic role in selected patients at high fracture risk, including trials with fracture and bone-density outcomes. The corpus also shows that therapeutic sequence matters: transitioning to or from antiresorptive agents can alter bone-density trajectories, and results cannot be pooled without accounting for prior treatment. Off-label fracture-healing and surgical applications are maintained as separate research lanes. Product equivalence, dosing schedule, geography, baseline risk, and duration remain material sources of heterogeneity.","openQuestions":"Which treatment sequences best preserve fracture-risk reduction after teriparatide discontinuation? Which patients derive sufficient incremental benefit to justify cost, injection burden, and safety monitoring? How should evidence be interpreted in advanced kidney disease, younger adults, pregnancy-associated osteoporosis, and rare bone disorders? Which fracture-healing and surgical findings replicate in adequately powered trials with patient-important outcomes? What duration and retreatment strategies optimize long-term benefit, and how should current product-specific labels and biosimilar comparability be incorporated?"},"completion":{"version":"wpf-profile-v1.0","complete":false,"checks":[{"key":"overview","passed":true,"actual":618,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":759,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":658,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":599,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":628,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":25,"required":25,"severity":"blocking"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["reviewed_sources","claims"]},"chemistry":{"id":"c439b58abdbf2f1acc1507df90f16e24","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","molecularFormula":"C181H291N55O51S2","molecularWeight":4118,"aminoAcidSequence":"SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF","smiles":"CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N","inchi":"InChI=1S/C181H291N55O51S2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97/h22-26,35-38,77-80,85-96,103,105-132,143-146,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,191,192,198)(H4,193,194,199)/t96-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,143-,144-,145-,146-/m0/s1","inchikey":"OGBMKVWORPGQRR-UMXFMPSGSA-N","structureImageUrl":"https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/16133850/PNG","createdAt":"2026-09-10T00:37:11.517Z","updatedAt":"2026-09-10T00:37:11.517Z"},"evidence":[{"id":"aaeabc7b99b05dfbc4bd011c8585aca8","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40047881/","evidenceTier":"observational","summary":"Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations.","authors":"Charlotte Beaudart, Nicola Veronese, Jonathan Douxfils, Jotheeswaran Amuthavalli Thiyagarajan, Francesco Bolzetta, Paolo Albanese, Gianpaolo Voltan, Majed Alokail, Nicholas C Harvey, Nicholas R Fuggle, Olivier Bruyère, René Rizzoli","publishingOrg":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","publicationYear":2025,"doi":"10.1007/s00198-025-07440-1","pubmedId":"40047881","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00198-025-07440-1","sourceIdentityId":"16e9a58522d8317c0b7bdc90ffc4a7e9","sourceStatus":"active","sourceContentHash":"7ececf23ad88d8f74e88f33117a9c8449e3945111225cbfb6b05be403e4f3518","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:40047881","evidenceLane":"meta_analysis","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review and meta-analysis","sourceStrength":{"grade":"A","score":88,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":70,"replication":70,"studyDesign":88,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s00198-025-07440-1","locator":"https://pubmed.ncbi.nlm.nih.gov/40047881/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"7ececf23ad88d8f74e88f33117a9c8449e3945111225cbfb6b05be403e4f3518","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"40047881","rawPayloadReference":"pubmed:40047881"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"a9e05d6fefb39ed1ce4144c230516ea9","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/39312040/","evidenceTier":"observational","summary":"The study found that in osteoporosis patients who had not previously received bisphosphonate treatment and were in a treatment cycle of over 12 months, both teriparatide and denosumab significantly increased bone mineral density compared to bisphosphonates.","authors":"Mingnian Li, Zhuoqi Ge, Benqi Zhang, Li Sun, Zhongyuan Wang, Tao Zou, Qi Chen","publishingOrg":"Archives of osteoporosis","publicationYear":2024,"doi":"10.1007/s11657-024-01447-7","pubmedId":"39312040","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s11657-024-01447-7","sourceIdentityId":"71efb4aad8a1c1e71cd8dc2d2b15fb61","sourceStatus":"active","sourceContentHash":"044cfa38a88145814902fc4de187cdc2d77f03a3164f7a7dd34e27309a407f2c","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:39312040","evidenceLane":"meta_analysis","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review and meta-analysis","sourceStrength":{"grade":"A","score":88,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":88,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s11657-024-01447-7","locator":"https://pubmed.ncbi.nlm.nih.gov/39312040/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"044cfa38a88145814902fc4de187cdc2d77f03a3164f7a7dd34e27309a407f2c","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"39312040","rawPayloadReference":"pubmed:39312040"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"4e381ec1032ae640ed849ae4fd42e5e1","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Biosimilarity Assessment of the Biosimilar Teriparatide Candidate and the Reference Drug in Healthy Subjects.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36710466/","evidenceTier":"phase_1_2","summary":"SAL001, a recombinant form of parathyroid hormone, is a biosimilar drug to teriparatide and is planned to be used in osteoporosis treatment.","authors":"Xuan Wang, Xintong Liang, Tenghua Wang, Yaoxuan Zhan, Haiyan Liu, Chen Li, Xianbo Li, Hui Ma, Zhiqin Hu, Xiaole Wang, Shuangshuang Xiao, Li Ban","publishingOrg":"Clinical pharmacology in drug development","publicationYear":2023,"doi":"10.1002/cpdd.1221","pubmedId":"36710466","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/cpdd.1221","sourceIdentityId":"b87d3c5ecd07904172275130dfc5de26","sourceStatus":"active","sourceContentHash":"00f2ef22bd7d296797af2da8a9616229442d0f0019ccb7a9ccc0f999e321b04e","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:36710466","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1002/cpdd.1221","locator":"https://pubmed.ncbi.nlm.nih.gov/36710466/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"00f2ef22bd7d296797af2da8a9616229442d0f0019ccb7a9ccc0f999e321b04e","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"36710466","rawPayloadReference":"pubmed:36710466"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"91fe23f577af8cc28eca5e8616e2d381","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36592455/","evidenceTier":"observational","summary":"The prevalence of osteoporosis is increasing in the United States.","authors":"Chelsea Ayers, Devan Kansagara, Brittany Lazur, Rongwei Fu, Amy Kwon, Curtis Harrod","publishingOrg":"Annals of internal medicine","publicationYear":2023,"doi":"10.7326/m22-0684","pubmedId":"36592455","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.7326/m22-0684","sourceIdentityId":"366f2969cd651458814c18fd82d8343b","sourceStatus":"active","sourceContentHash":"30c999e08891458cbf6437935ba7fe26b1b94889aade2e1234cae3d5089418a1","sourceVersion":1,"retrievedAt":"2026-09-10T09:03:07.508Z","retrievalProvider":"pubmed","retrievalPayloadRef":"pubmed:36592455","evidenceLane":null,"extractionPayload":null,"provenancePayload":{"locator":"https://pubmed.ncbi.nlm.nih.gov/36592455/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-10T09:03:07.508Z","rawPayloadHash":"30c999e08891458cbf6437935ba7fe26b1b94889aade2e1234cae3d5089418a1","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"36592455","rawPayloadReference":"pubmed:36592455"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":false,"required":true,"reasonCodes":["extraction_not_grounded_or_verified"]},{"id":"G5","passed":false,"required":true,"reasonCodes":["evidence_lane_unresolved"]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"quarantine","reasonCodes":["extraction_not_grounded_or_verified","evidence_lane_unresolved"],"catastrophic":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","roleDemotedFromPromotion":[],"admitsExactPublishedEvidence":true},"engineState":"quarantined","engineRunId":"be21bd35-91c5-43ed-8852-6e31f85ded4c","createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T09:03:25.533Z"},{"id":"90d2d501dbace0574eeed9fbd87e0bb7","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36239756/","evidenceTier":"phase_1_2","summary":"In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower incidence of morphometric vertebral fracture than monotherapy with alendronate for 120 weeks in women with osteoporosis at high risk of fracture.","authors":"Satoshi Mori, Hiroshi Hagino, Toshitsugu Sugimoto, Shiro Tanaka, Yuji Mitomo, Kaito Takahashi, Teruki Sone, Toshitaka Nakamura, Satoshi Soen","publishingOrg":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","publicationYear":2023,"doi":"10.1007/s00198-022-06570-0","pubmedId":"36239756","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00198-022-06570-0","sourceIdentityId":"ff95d543b89504951eb7f4ceb770bbbd","sourceStatus":"active","sourceContentHash":"7379d380088024c789e3d0e139da2afaccc1a0b9d6b24d4fe0d3fdefaa2ecbe7","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:36239756","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s00198-022-06570-0","locator":"https://pubmed.ncbi.nlm.nih.gov/36239756/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"7379d380088024c789e3d0e139da2afaccc1a0b9d6b24d4fe0d3fdefaa2ecbe7","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"36239756","rawPayloadReference":"pubmed:36239756"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"cc7fc4d18e96b35491be1c20dbc2a0d4","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/35398293/","evidenceTier":"phase_1_2","summary":"The effects of daily teriparatide (20 μg) (D-PTH), weekly high-dose teriparatide (56.5 μg) (W-PTH), or bisphosphonates (BPs) on areal bone mineral density (aBMD), bone turnover markers (BTMs), volumetric BMD (vBMD), microarchitecture, and estimated strength were investigated in postmenopausal osteoporosis patients.","authors":"Ko Chiba, Narihiro Okazaki, Ayako Kurogi, Tsuyoshi Watanabe, Ai Mori, Nobuhiko Suzuki, Koichi Adachi, Makoto Era, Kazuaki Yokota, Takuma Inoue, Yoshihiro Yabe, Keizo Furukawa","publishingOrg":"Bone","publicationYear":2022,"doi":"10.1016/j.bone.2022.116416","pubmedId":"35398293","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.bone.2022.116416","sourceIdentityId":"a69f8a6164eda3d3328bf2f865a85e53","sourceStatus":"active","sourceContentHash":"893fe21c2a3b412f4c3ad3babcf1bbf7620cbe604cb7250faf3c1df6eca0eafa","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:35398293","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.bone.2022.116416","locator":"https://pubmed.ncbi.nlm.nih.gov/35398293/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"893fe21c2a3b412f4c3ad3babcf1bbf7620cbe604cb7250faf3c1df6eca0eafa","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"35398293","rawPayloadReference":"pubmed:35398293"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"842ac646c2c657da37e65196d8d5a70f","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/34383100/","evidenceTier":"phase_1_2","summary":"Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months.","authors":"J W Nieves, F Cosman, D McMahon, M Redko, I Hentschel, R Bartolotta, M Loftus, J J Kazam, J Rotman, J Lane","publishingOrg":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","publicationYear":2022,"doi":"10.1007/s00198-021-06065-4","pubmedId":"34383100","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00198-021-06065-4","sourceIdentityId":"bd7d6a5b1929a9acb622e0e831d00275","sourceStatus":"active","sourceContentHash":"887d5eec3d09c7131cf762e640e3366982fac3d708dff13833efe5858ae5d94d","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:34383100","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s00198-021-06065-4","locator":"https://pubmed.ncbi.nlm.nih.gov/34383100/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"887d5eec3d09c7131cf762e640e3366982fac3d708dff13833efe5858ae5d94d","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"34383100","rawPayloadReference":"pubmed:34383100"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"24022a031bf625672a9fb9bde1daba02","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Teriparatide treatment in severe osteoporosis - a controlled 10-year follow-up study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36424580/","evidenceTier":"phase_1_2","summary":"Teriparatide was the first anabolic agent recommended for the treatment of osteoporosis.","authors":"Georgios Kontogeorgos, Emily Krantz, Penelope Trimpou, Christine M Laine, Kerstin Landin-Wilhelmsen","publishingOrg":"BMC musculoskeletal disorders","publicationYear":2022,"doi":"10.1186/s12891-022-05987-2","pubmedId":"36424580","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1186/s12891-022-05987-2","sourceIdentityId":"b114b86867a25595eb4b6393d9e89565","sourceStatus":"active","sourceContentHash":"6454f0862d9505592443081b641cf379a87c217bd9dd658c7943069cb5fd0ee9","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:36424580","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1186/s12891-022-05987-2","locator":"https://pubmed.ncbi.nlm.nih.gov/36424580/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"6454f0862d9505592443081b641cf379a87c217bd9dd658c7943069cb5fd0ee9","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"36424580","rawPayloadReference":"pubmed:36424580"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"f0e55845128d138e86edf8f2e0edb10b","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/32588816/","evidenceTier":"observational","summary":"Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture.","authors":"Sarah Davis, Emma Simpson, Jean Hamilton, Marrissa Martyn-St James, Andrew Rawdin, Ruth Wong, Edward Goka, Neil Gittoes, Peter Selby","publishingOrg":"Health technology assessment (Winchester, England)","publicationYear":2020,"doi":"10.3310/hta24290","pubmedId":"32588816","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3310/hta24290","sourceIdentityId":"bf11416b45c0b2a17e07d880c1203d0d","sourceStatus":"active","sourceContentHash":"5359b6bf9a990bb44811964051b652f0a832d252fa45ef4306c08e9890fbbbef","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:32588816","evidenceLane":"meta_analysis","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review and meta-analysis","sourceStrength":{"grade":"A","score":88,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":88,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.3310/hta24290","locator":"https://pubmed.ncbi.nlm.nih.gov/32588816/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"5359b6bf9a990bb44811964051b652f0a832d252fa45ef4306c08e9890fbbbef","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"32588816","rawPayloadReference":"pubmed:32588816"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"f825487e92c076169317d0fa9d840928","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/31419313/","evidenceTier":"phase_1_2","summary":"In the absence of an intervening antiresorptive agent, cyclic administration of teriparatide does not increase bone mineral density (BMD) more than standard daily therapy.","authors":"Felicia Cosman, Donald McMahon, David Dempster, Jeri W Nieves","publishingOrg":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","publicationYear":2020,"doi":"10.1002/jbmr.3850","pubmedId":"31419313","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/jbmr.3850","sourceIdentityId":"3ecf22311833d3ec9c5ee934039593a3","sourceStatus":"active","sourceContentHash":"13f6eaeb2239c04d188772f0cbd6d9010b069f5ec60594a155bb3efebb465543","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:31419313","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1002/jbmr.3850","locator":"https://pubmed.ncbi.nlm.nih.gov/31419313/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"13f6eaeb2239c04d188772f0cbd6d9010b069f5ec60594a155bb3efebb465543","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"31419313","rawPayloadReference":"pubmed:31419313"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"ab0369c64072c4d0d5703e9fd3265a19","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/32614699/","evidenceTier":"phase_1_2","summary":"Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent but morbid and potentially serious condition associated with antiresorptive and antiangiogenic therapies.","authors":"Ie-Wen Sim, Gelsomina L Borromeo, Claudine Tsao, Rita Hardiman, Michael S Hofman, Christian Papatziamos Hjelle, Musib Siddique, Gary J R Cook, John F Seymour, Peter R Ebeling","publishingOrg":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","publicationYear":2020,"doi":"10.1200/jco.19.02192","pubmedId":"32614699","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1200/jco.19.02192","sourceIdentityId":"1400c0cab38df3f44e7d2de6c5bfafde","sourceStatus":"active","sourceContentHash":"e783feb5dc3b7496cec1034b056339499c775c2c2d851d17ca470168f8b2a2d6","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:32614699","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1200/JCO.19.02192","locator":"https://pubmed.ncbi.nlm.nih.gov/32614699/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"e783feb5dc3b7496cec1034b056339499c775c2c2d851d17ca470168f8b2a2d6","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"32614699","rawPayloadReference":"pubmed:32614699"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"0e894360d9a41b6575bf754a5478ed2d","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/31265071/","evidenceTier":"observational","summary":"Teriparatide and denosumab are effective treatments for osteoporosis and typically reserved as second-line options after patients have used bisphosphonates.","authors":"Houchen Lyu, Sizheng S Zhao, Kazuki Yoshida, Sara K Tedeschi, Chang Xu, Sagar U Nigwekar, Benjamin Z Leder, Daniel H Solomon","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2019,"doi":"10.1210/jc.2019-00924","pubmedId":"31265071","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2019-00924","sourceIdentityId":"f86cd87881e859cbe2b827e7db697089","sourceStatus":"active","sourceContentHash":"b51eda1ba7dbd56b1ccccce285d08c491fc326e63ce9e2521d8e6998c964f20f","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:31265071","evidenceLane":"human_observational","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"observational, comparative, monitoring, or contextual human study","sourceStrength":{"grade":"B","score":75,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":75,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jc.2019-00924","locator":"https://pubmed.ncbi.nlm.nih.gov/31265071/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"b51eda1ba7dbd56b1ccccce285d08c491fc326e63ce9e2521d8e6998c964f20f","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"31265071","rawPayloadReference":"pubmed:31265071"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"6ff99b045b2b29e9927d44f3b57976c1","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/29129436/","evidenceTier":"phase_1_2","summary":"No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome.","authors":"David L Kendler, Fernando Marin, Cristiano A F Zerbini, Luis A Russo, Susan L Greenspan, Vit Zikan, Alicia Bagur, Jorge Malouf-Sierra, Péter Lakatos, Astrid Fahrleitner-Pammer, Eric Lespessailles, Salvatore Minisola","publishingOrg":"Lancet (London, England)","publicationYear":2018,"doi":"10.1016/s0140-6736(17)32137-2","pubmedId":"29129436","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(17)32137-2","sourceIdentityId":"656e50b375476773c2e63ab462a53447","sourceStatus":"active","sourceContentHash":"1064054079bbccce1d268a7f7b9bf4f020657c93807db74fb7ca176db27f98c3","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:29129436","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/S0140-6736(17)32137-2","locator":"https://pubmed.ncbi.nlm.nih.gov/29129436/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"1064054079bbccce1d268a7f7b9bf4f020657c93807db74fb7ca176db27f98c3","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"29129436","rawPayloadReference":"pubmed:29129436"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"cc3f4d17b314eb8337bfc4d67ce632d0","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/27840301/","evidenceTier":"phase_1_2","summary":"While changes in biochemical markers of bone turnover (BTM) have been reported to predict changes in bone mineral density (BMD), the relationship between changes in BMD and BTMs with combined antiresorptive/anabolic therapy is unknown.","authors":"J N Tsai, S M Burnett-Bowie, H Lee, B Z Leder","publishingOrg":"Bone","publicationYear":2017,"doi":"10.1016/j.bone.2016.11.009","pubmedId":"27840301","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.bone.2016.11.009","sourceIdentityId":"1253af577429a467b6b46a8089a4708a","sourceStatus":"active","sourceContentHash":"2dd8e69f2ed7412fb73269afcbd135343132c9d68613f967a5cd3111f07b5213","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:27840301","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.bone.2016.11.009","locator":"https://pubmed.ncbi.nlm.nih.gov/27840301/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"2dd8e69f2ed7412fb73269afcbd135343132c9d68613f967a5cd3111f07b5213","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"27840301","rawPayloadReference":"pubmed:27840301"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"0433039100c6415f6084e97572dc7831","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Relative bioavailability between two teriparatide formulations in healthy volunteers.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/27007999/","evidenceTier":"phase_1_2","summary":"To compare the pharmacokinetics, relative bioavailability (RB), immunogenicity, and safety after a single dose of test or reference formulation of teriparatide in healthy human volunteers in order to demonstrate whether both products are similar.","authors":"Javier Farías, Guillermo A Keller, Mariana Papouchado, María C Villa Etchegoyen, Marcelo E Criscuolo, Roberto A Diez, Guillermo Di Girolamo","publishingOrg":"International journal of clinical pharmacology and therapeutics","publicationYear":2016,"doi":"10.5414/cp202562","pubmedId":"27007999","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.5414/cp202562","sourceIdentityId":"90b08fd81dd6aeb8d8db0d17c0ba9ae2","sourceStatus":"active","sourceContentHash":"49eade062cfa85bed37dd58cf8dbf0e7916208788e4b9fb8ad9c41e230798a23","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:27007999","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.5414/CP202562","locator":"https://pubmed.ncbi.nlm.nih.gov/27007999/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"49eade062cfa85bed37dd58cf8dbf0e7916208788e4b9fb8ad9c41e230798a23","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"27007999","rawPayloadReference":"pubmed:27007999"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"ca7c29b7d152ad252c260ed5e93a4f79","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/27462147/","evidenceTier":"observational","summary":"This postmarketing surveillance study assessed the safety and effectiveness of teriparatide in patients with osteoporosis at high risk of fracture in Japan.","authors":"Atsushi Nishikawa, Takehiro Ishida, Masanori Taketsuna, Fumito Yoshiki, Hiroyuki Enomoto","publishingOrg":"Clinical interventions in aging","publicationYear":2016,"doi":"10.2147/cia.s107285","pubmedId":"27462147","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2147/cia.s107285","sourceIdentityId":"9850172922aa1ea65b1ed2d5d15e1fa7","sourceStatus":"active","sourceContentHash":"dbc02474f4fc02664cc7851780c8735ba09fdd09fd4d68938f6526aafbe0792d","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:27462147","evidenceLane":"human_observational","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"observational, comparative, monitoring, or contextual human study","sourceStrength":{"grade":"B","score":75,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":75,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.2147/CIA.S107285","locator":"https://pubmed.ncbi.nlm.nih.gov/27462147/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"dbc02474f4fc02664cc7851780c8735ba09fdd09fd4d68938f6526aafbe0792d","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"27462147","rawPayloadReference":"pubmed:27462147"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"de5c012da91a63ebf43c0251d5bc63ce","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26144908/","evidenceTier":"phase_1_2","summary":"Unlike most chronic diseases, osteoporosis treatments are generally limited to a single drug at a fixed dose and frequency.","authors":"Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Paul M Wallace, Hang Lee, Robert M Neer, Sherri-Ann M Burnett-Bowie","publishingOrg":"Lancet (London, England)","publicationYear":2015,"doi":"10.1016/s0140-6736(15)61120-5","pubmedId":"26144908","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(15)61120-5","sourceIdentityId":"e42ec08d846c149a76e84a2d91df4f59","sourceStatus":"active","sourceContentHash":"a68db0ef464ce8d3ca7efb4627867a52cfcb655f5905202363075cc383c84312","sourceVersion":1,"retrievedAt":"2026-09-10T09:03:07.508Z","retrievalProvider":"pubmed","retrievalPayloadRef":"pubmed:26144908","evidenceLane":null,"extractionPayload":null,"provenancePayload":{"locator":"https://pubmed.ncbi.nlm.nih.gov/26144908/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-10T09:03:07.508Z","rawPayloadHash":"a68db0ef464ce8d3ca7efb4627867a52cfcb655f5905202363075cc383c84312","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"26144908","rawPayloadReference":"pubmed:26144908"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":false,"required":true,"reasonCodes":["extraction_not_grounded_or_verified"]},{"id":"G5","passed":false,"required":true,"reasonCodes":["evidence_lane_unresolved"]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"quarantine","reasonCodes":["extraction_not_grounded_or_verified","evidence_lane_unresolved"],"catastrophic":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","roleDemotedFromPromotion":[],"admitsExactPublishedEvidence":true},"engineState":"quarantined","engineRunId":"be21bd35-91c5-43ed-8852-6e31f85ded4c","createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T09:03:43.500Z"},{"id":"8747ed8824057cbe7cecc0f915024023","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26092062/","evidenceTier":"phase_3","summary":"The aim of this study was to determine the efficacy of once-weekly teriparatide as a function of baseline fracture risk.","authors":"N C Harvey, J A Kanis, A Odén, T Nakamura, M Shiraki, T Sugimoto, T Kuroda, H Johansson, E V McCloskey","publishingOrg":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","publicationYear":2015,"doi":"10.1007/s00198-015-3129-7","pubmedId":"26092062","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00198-015-3129-7","sourceIdentityId":"2289b27460c46787b2e9fc11a8b181b4","sourceStatus":"active","sourceContentHash":"2a019b3cf85d9d5dfd08ebce82c1051347ec5c1bdd34e6ca17ae597a767a8d29","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:26092062","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s00198-015-3129-7","locator":"https://pubmed.ncbi.nlm.nih.gov/26092062/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"2a019b3cf85d9d5dfd08ebce82c1051347ec5c1bdd34e6ca17ae597a767a8d29","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"26092062","rawPayloadReference":"pubmed:26092062"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"d49bc556af9f7b0da981ac280a72bad8","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26092063/","evidenceTier":"phase_1_2","summary":"Daily teriparatide injections have been shown to reduce vertebral and non-vertebral fractures.","authors":"N C Harvey, J A Kanis, A Odén, R T Burge, B H Mitlak, H Johansson, E V McCloskey","publishingOrg":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","publicationYear":2015,"doi":"10.1007/s00198-015-3173-3","pubmedId":"26092063","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00198-015-3173-3","sourceIdentityId":"28eb0ae1d5c51d8cd9b1f2ba6a2bcd3d","sourceStatus":"active","sourceContentHash":"a96152c040cad547cc730c296a04913bdecacd710ec0be0f6569389d2aa77536","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:26092063","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s00198-015-3173-3","locator":"https://pubmed.ncbi.nlm.nih.gov/26092063/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"a96152c040cad547cc730c296a04913bdecacd710ec0be0f6569389d2aa77536","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"26092063","rawPayloadReference":"pubmed:26092063"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"cc788a9eb6991a6d451f112bb27cbd36","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/24517156/","evidenceTier":"phase_1_2","summary":"Current osteoporosis medications increase bone mineral density (BMD) modestly and reduce, but do not eliminate, fracture risk.","authors":"Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Sherri-Ann M Burnett-Bowie, Yuli Zhu, Katelyn Foley, Hang Lee, Robert M Neer","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2014,"doi":"10.1210/jc.2013-4440","pubmedId":"24517156","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2013-4440","sourceIdentityId":"cf5e5595b081a969731b73d4cb4ffe56","sourceStatus":"active","sourceContentHash":"637b3e87993fb7e8865531423e1d787a71239886418f40b5f8c121bfd970f640","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:24517156","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jc.2013-4440","locator":"https://pubmed.ncbi.nlm.nih.gov/24517156/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"637b3e87993fb7e8865531423e1d787a71239886418f40b5f8c121bfd970f640","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"24517156","rawPayloadReference":"pubmed:24517156"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"fba453eb1f3d30381fd50af946154c76","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/23683600/","evidenceTier":"phase_1_2","summary":"Osteoporosis medications increase bone-mineral density (BMD) and lower but do not eliminate fracture risk.","authors":"Joy N Tsai, Alexander V Uihlein, Hang Lee, Ruchit Kumbhani, Erica Siwila-Sackman, Elizabeth A McKay, Sherri-Ann M Burnett-Bowie, Robert M Neer, Benjamin Z Leder","publishingOrg":"Lancet (London, England)","publicationYear":2013,"doi":"10.1016/s0140-6736(13)60856-9","pubmedId":"23683600","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(13)60856-9","sourceIdentityId":"585416251fef692677c50ed9b45eebed","sourceStatus":"active","sourceContentHash":"cbd99c50185b0ae68a03c32f25e9192d7f13b99072902dff913e2e0cef43a487","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:23683600","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/S0140-6736(13)60856-9","locator":"https://pubmed.ncbi.nlm.nih.gov/23683600/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"cbd99c50185b0ae68a03c32f25e9192d7f13b99072902dff913e2e0cef43a487","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"23683600","rawPayloadReference":"pubmed:23683600"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"508f3354e364bc1d141cb022bf03440f","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/22036910/","evidenceTier":"phase_1_2","summary":"In the Fracture Prevention Trial, the risks of any nonvertebral fracture (relative risk [RR] 0.65, P=0.04) and any fragility nonvertebral fracture (RR 0.47, P=0.02) were significantly reduced in the teriparatide 20 μg/day (teriparatide) versus placebo group.","authors":"J H Krege, X Wan","publishingOrg":"Bone","publicationYear":2012,"doi":"10.1016/j.bone.2011.10.018","pubmedId":"22036910","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.bone.2011.10.018","sourceIdentityId":"8a91f2a1b2fc1b701b9cdd87bc61c7e3","sourceStatus":"active","sourceContentHash":"1603ee864bd49b8352d1b63944f76c77e3a477cf324041172dd4f96023961699","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:22036910","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.bone.2011.10.018","locator":"https://pubmed.ncbi.nlm.nih.gov/22036910/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"1603ee864bd49b8352d1b63944f76c77e3a477cf324041172dd4f96023961699","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"22036910","rawPayloadReference":"pubmed:22036910"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"c66f1fefd1e317bd5c45c82ff8b6c7e5","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/18003959/","evidenceTier":"phase_1_2","summary":"Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis.","authors":"Kenneth G Saag, Elizabeth Shane, Steven Boonen, Fernando Marín, David W Donley, Kathleen A Taylor, Gail P Dalsky, Robert Marcus","publishingOrg":"The New England journal of medicine","publicationYear":2007,"doi":"10.1056/nejmoa071408","pubmedId":"18003959","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1056/nejmoa071408","sourceIdentityId":"50faeb48d312217061847cca4f0bcdfb","sourceStatus":"active","sourceContentHash":"f0aa9adfa4bf836eff9a6b6579f905035b9457201767fa64f17f9db23ec97257","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:18003959","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1056/NEJMoa071408","locator":"https://pubmed.ncbi.nlm.nih.gov/18003959/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"f0aa9adfa4bf836eff9a6b6579f905035b9457201767fa64f17f9db23ec97257","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"18003959","rawPayloadReference":"pubmed:18003959"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"cf1356e1d6c8ecc880d5790251a35b7b","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/15613428/","evidenceTier":"phase_1_2","summary":"The relationship between prior fractures and risk of new fractures was evaluated in 931 postmenopausal women with prevalent vertebral fractures randomized to daily placebo or teriparatide (20 mug) in the Fracture Prevention Trial.","authors":"J Christopher Gallagher, Harry K Genant, Gerald G Crans, Socorro Juan Vargas, John H Krege","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2005,"doi":"10.1210/jc.2004-0826","pubmedId":"15613428","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2004-0826","sourceIdentityId":"bd75ac6964e5332d9471d800ed1d9982","sourceStatus":"active","sourceContentHash":"ba3fbbd1a8727b6babcb18a66cd69709f74765d853c780e316a5573ab15ac945","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:15613428","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jc.2004-0826","locator":"https://pubmed.ncbi.nlm.nih.gov/15613428/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"ba3fbbd1a8727b6babcb18a66cd69709f74765d853c780e316a5573ab15ac945","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"15613428","rawPayloadReference":"pubmed:15613428"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"},{"id":"83c837ae9164d7c08f0aabacdce16bb4","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","title":"Teriparatide (forteo) for osteoporsis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/12571538/","evidenceTier":"phase_1_2","summary":"PubMed-indexed source directly addressing teriparatide within its stated study design.","authors":"","publishingOrg":"The Medical letter on drugs and therapeutics","publicationYear":2003,"doi":null,"pubmedId":"12571538","jurisdiction":null,"dateAccessed":"2026-09-10T00:34:09.792Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the teriparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:12571538","sourceIdentityId":"59712f29914e3fb78e2ab30e8ba6b2b3","sourceStatus":"active","sourceContentHash":"8b28dfd2db77bd425544276c4c248dff6c0e17b708833f53a3d233327a92c098","sourceVersion":1,"retrievedAt":"2026-09-10T00:34:09.792Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:12571538","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":null,"locator":"https://pubmed.ncbi.nlm.nih.gov/12571538/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"8b28dfd2db77bd425544276c4c248dff6c0e17b708833f53a3d233327a92c098","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"12571538","rawPayloadReference":"pubmed:12571538"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-10T00:34:09.792Z","updatedAt":"2026-09-10T00:43:54.228Z"}],"regulatory":[{"id":"3c3257e222992d89dbb012de9a851a5f","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","jurisdiction":"United States (FDA — BONSITY)","status":"approved","approvedIndication":"BONSITY teriparatide is FDA-approved as a prescription subcutaneous teriparatide product for its labeled osteoporosis indications and populations.","rationale":"This distinct application documents product-specific authorization. Formulation, device, labeling, eligibility, duration, and safety requirements govern; authorization must not be generalized to unapproved products or uses.","sourceTitle":"FDA Drugs@FDA — BONSITY NDA 211939","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211939","dateChecked":"2026-09-10T00:37:11.517Z","reviewDueAt":"2026-12-09T00:37:11.517Z","enteredById":null,"reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-10T00:37:11.517Z","updatedAt":"2026-09-10T00:43:54.235Z"},{"id":"9404fec00ef81a2efeb817eafc3979ce","peptideId":"eca01bfe-966d-48c4-9366-6b3f773b03ae","jurisdiction":"United States (FDA — FORTEO)","status":"approved","approvedIndication":"FORTEO teriparatide is FDA-approved for labeled osteoporosis indications in specified patients at high fracture risk; the current product, strength, route, duration guidance, warnings, and patient-selection language control.","rationale":"The authorization is specific to the FDA-approved subcutaneous product and labeled populations. It does not establish routine use for fracture healing, spinal fusion, osteonecrosis of the jaw, or other off-label applications.","sourceTitle":"FDA Drugs@FDA — FORTEO NDA 021318","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021318","dateChecked":"2026-09-10T00:37:11.517Z","reviewDueAt":"2026-12-09T00:37:11.517Z","enteredById":null,"reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-10T00:37:11.517Z","updatedAt":"2026-09-10T00:43:54.235Z"}],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}